Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 30, 2002

View Archived Issues

New data on the efficacy and safety of valdecoxib

ABI-007 trial cleared to continue

Novel antifungal compound SF-2822 described by Meiji Seika researchers

Sankyo patents new antibacterial agents isolated from Streptomyces cultures

Antifungal cyclic peptides prepared and tested at Takara Shuzo

Cell Therapeutics presents new inhibitors of IL-12 and IL-4 signaling for asthma, diabetes, etc.

New DPP-IV inhibitors in early development at Boehringer Ingelheim

Toyama presents novel agents with neuroprotective and neurotrophic activity

Banyu describes novel compounds able to increase GLP-1 levels

Keryx extends international manufacturing and negotiating rights for KRX-101

CollaGenex signs copromotion deal with Novartis for Denavir

Saegis licenses preclinical compound from Lilly for cognitive impairment

British Biotech and Serono extend antiinflammatory research agreement

First of three pivotal phase III trials of AC-2993 in type 2 diabetes completes enrollment

Inhibition of p38 MAP kinase associated with significant antiinflammatory effects in CIA

Two Genzyme enzyme replacement therapies up for FDA panel review in January

Pascolizumab characterized preclinically prior to clinical studies

Octapeptide based on alpha-MSH combines both antiinflammatory and antiinfective properties

Further development of LY-333531 for diabetic neuropathy and vasculopathy warranted

Potent and gut-selective Ca2+ channel antagonist with potential in IBS

GSK and Biosynexus to develop and commercialize staphylococcal antibodies and vaccines

Phase III Provenge trial resumes enrollment

Second Allox phase I/II trial completed

Chiron announces discontinuation of various programs

Cerebril phase II IND cleared

COGNIShunt system receives European regulatory approval

Statin induces apoptosis in RA synoviocytes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...